Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Haeck

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Investigative Dermatology|May 25, 2012
Modulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitisEdward F Knol, Inge M Haeck, Annemieke A van Kraats, et al.
The British Journal of Dermatology|August 14, 2009
Low bone mineral density in adult patients with moderate to severe atopic dermatitisI M Haeck, N A T Hamdy, L Timmer-de Mik, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|February 5, 2025
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitisLisa P van der Rijst, Nienke Veldhuis, Sara van der Kamp, et al.
Expert Opinion on Biological Therapy|December 1, 2025
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatmentCeleste M Boesjes, Lian F van der Gang, Roselie E Achten, et al.
Elife|June 19, 2023
Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentrationSatish Rojekar, Anusha R Pallapati, Judit Gimenez-Roig, et al.
Journal of the American Academy of Dermatology|August 17, 2010
Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitisJohanna M Kwakkel-van Erp, Inge M Haeck, Annelieke W M Paantjens, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Bone mineral density in children with moderate to severe atopic dermatitisSara Gertrudes Anna van Velsen, Mirjam J Knol, Rachel L A van Eijk, et al.
The British Journal of Dermatology|May 13, 2023
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registryLotte S Spekhorst, Celeste M Boesjes, Laura Loman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2026
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDayLian F van der Gang, Nicolaas P A Zuithoff, Inge M Haeck, et al.
American Journal of Clinical Dermatology|May 27, 2024
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis TreatmentSarah E Thomas, Marieke M B Seyger, Josje E Mangnus, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Investigative Dermatology|May 25, 2012
Modulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitisEdward F Knol, Inge M Haeck, Annemieke A van Kraats, et al.
The British Journal of Dermatology|August 14, 2009
Low bone mineral density in adult patients with moderate to severe atopic dermatitisI M Haeck, N A T Hamdy, L Timmer-de Mik, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|February 5, 2025
Ocular surface disease in pediatric patients with moderate-to-severe atopic dermatitisLisa P van der Rijst, Nienke Veldhuis, Sara van der Kamp, et al.
Expert Opinion on Biological Therapy|December 1, 2025
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatmentCeleste M Boesjes, Lian F van der Gang, Roselie E Achten, et al.
Elife|June 19, 2023
Development and biophysical characterization of a humanized FSH-blocking monoclonal antibody therapeutic formulated at an ultra-high concentrationSatish Rojekar, Anusha R Pallapati, Judit Gimenez-Roig, et al.
Journal of the American Academy of Dermatology|August 17, 2010
Differential usefulness of biomarkers thymus and activation-regulated chemokine and soluble CD30 during enteric coated mycophenolate sodium and cyclosporine therapy in atopic dermatitisJohanna M Kwakkel-van Erp, Inge M Haeck, Annelieke W M Paantjens, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Bone mineral density in children with moderate to severe atopic dermatitisSara Gertrudes Anna van Velsen, Mirjam J Knol, Rachel L A van Eijk, et al.
The British Journal of Dermatology|May 13, 2023
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registryLotte S Spekhorst, Celeste M Boesjes, Laura Loman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2026
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDayLian F van der Gang, Nicolaas P A Zuithoff, Inge M Haeck, et al.
American Journal of Clinical Dermatology|May 27, 2024
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis TreatmentSarah E Thomas, Marieke M B Seyger, Josje E Mangnus, et al.
Pageof 4